SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!

MITUMITU

info@mitu.or.tz | +255 28 2500019 | Staff Mail
  • LOGIN
  • WHO WE ARE
    • History & Background
    • Mission & Values
    • Strategic Plan
    • Organization Structure
    • Our Team
  • WHERE WE ARE
    • Mwanza Medical Research Centre
    • Mwanza City
  • WHAT WE DO
    • Research Programme
    • Capacity Building
    • Research Facilities
  • PUBLICATIONS
  • NEWS & EVENTS
    • News & Events
    • Career
  • CONTACT US
Thursday, 09 June 2022 / Published in News

MITU launches a new human papilloma virus (HPV) vaccine trial among boys in  Tanzania

Mwanza Intervention Trials Unit (MITU) has launched a new trial of human papilloma virus (HPV) vaccine (“Add-Vacc Trial”).  HPV vaccination has been included within the Tanzania national vaccination programme since 2018 and is delivered to girls around 14 years of age to protect them from cervical cancer. Apart from being the main cause of cervical cancer, HPV virus also causes other health problems including anogenital warts and other less common forms of cancer, such as penile cancer, anal cancer and throat cancer.

Staged-consent-process

Staged consent process

Over the course of three years, the Add-Vacc trial will investigate the benefits of adding male vaccination to the existing national programme of female HPV vaccination in Tanzania. A number of countries have begun vaccinating boys in addition to girls – known as gender neutral vaccination. Vaccinating males can protect them from health problems caused by HPV virus infection while at the same time preventing them from passing the virus on to their unvaccinated female partners. This could help reduce the amount of HPV infection and associated health problems in the community.

Country side where the trial will take place

Twenty-six communities will be randomly assigned to receive either the intervention (male HPV vaccination plus female vaccination as part of the ongoing national vaccination programme) or the control condition (only female vaccination as part of the ongoing national vaccination programme). A single dose of male HPV vaccination will be provided to males 14-18 years of age. Two household surveys will be conducted – one before male vaccination is implemented and another one three years later, to assess whether this added vaccination reduces the amount of HPV infection present in the communities. Social science research will be conducted as part of this trial to help the research team to better understand community knowledge and perceptions of HPV vaccination.

Dr. Victoria Ewing who is coordinating the implementation of this trial said, “This trial is important because giving a single dose of HPV vaccine to males might provide a simple and cost-effective way to reduce the amount of HPV infection in the community. We are excited to be the first to conduct a trial of HPV vaccination in boys in sub-Saharan Africa.”

This trial is led by Prof. Debby Watson-Jones and Dr. Kathy Baisley from the London School of Hygiene & Tropical Medicine, and John Changalucha from MITU.

What you can read next

Working remotely at MITU in response to COVID-19 pandemic
MITU Holds a Meeting of Water, Sanitation and Hygiene (WASH) Stakeholders
HIV prevention: not hitting the mark

Filter by Year

  • All Publications
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003

Recent Posts

  • A study protocol to engage religious leaders to reduce blood pressure in Tanzanian communities: A cluster randomized trial.

  • Exposure to toxic chemical elements (Pb, Cd, and Hg) and its association with sustained high blood pressure among secondary school attending adolescents in Northwestern Tanzania. Nsanya MK, Willkens M, Peck RN, Kapiga SH, Nyanza EC. Environ Res. 2025 Apr 29;278:121738. DOI: 10.1016/j.envres.2025.121738. Epub ahead of print. PMID: 40311907.

  • A multifaceted menstrual health intervention to improve psychosocial outcomes and menstrual practices among secondary schoolgirls in Northwest Tanzania: a pilot intervention study.

  • Validation of rapid point-of-care tests for herpes simplex virus-type 2 in rural Tanzania.

  • Arterial stiffness in people with HIV: a cross-sectional, comparative study with echocardiographic outcomes in Tanzania.

Receive our latest news straight to your inbox

CONTACT US

Contact us through the address below
Mwanza Intervention Trials Unit.

MITU, Isamilo Street,
P.O. Box11936,
Mwanza, Tanzania.

info@mitu.or.tz

+255 28 2500019

WHO WE ARE

  • History & Background
  • Mission & Values
  • Strategic Plan
  • Organization Structure
  • Our Team

WHAT WE DO

  • Research Programme
  • Capacity Building
  • Research Facilities

OUR SOCIAL

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram

OUR PARTNERS

Tweets by mituorg
© 2021 MITU | All rights reserved.
TOP